Patient-centred standards of care for adults with myositis
https://doi.org/10.1186/s41927-017-0002-7
© The Author(s) 2017
Received: 31 May 2017
Accepted: 19 October 2017
Published: 28 November 2017
Abstract
Background
The idiopathic inflammatory myopathies (IIM, myositis) are a heterogeneous group of chronic autoimmune disorders causing considerable physical and mental health impact. There is a lack of formalised guidance defining best practice for the management of myositis, contributing to inconsistent care provision and some patients feeling isolated and unsupported.
To address these issues, we evaluated the clinical services available to adults with myositis in the UK. We then created patient-centred standards of care using a structured process involving patients, their relatives and caregivers, physicians and allied healthcare professionals.
Methods
After an initial focus group, the clinical services available to patients with myositis were evaluated using a patient-completed questionnaire. Draft standards of care were created, each addressing deficits in care provision identified by patients. In response to feedback, including a two-stage modified Delphi exercise, these draft standards were iteratively improved until consensus was reached. Accompanying plain language versions of the standards of care and an audit tool were also created.
Results
We identified issues regarding diagnostic pathways, access to specialist services, advice and support regarding employment, medication-related adverse events and the treatment of extra-muscular manifestations. Fifteen standards of care were drafted. After modification, agreement was reached on eleven final standards of care.
Conclusion
These patient-centred standards of care for adults with myositis provide a benchmark for the evaluation of local practice. Their implementation will promote consistent good practice across care providers and empower patients when seeking access to local services.
Keywords
Background
The idiopathic inflammatory myopathies (IIM, myositis) are a heterogeneous group of long-term autoimmune inflammatory conditions. Myositis negatively impacts the quality of life of an estimated 250,000 patients worldwide [1]. A lack of formalised guidance defining best practice contributes to inconsistent care provision and may influence clinical outcomes.
In circumstances where evidence-based or data-driven approaches are not possible, or not yet available, the production of standards of care allows healthcare professionals to benchmark their service using a set of agreed ‘minimum’ or ‘optimum’ consensus standards. This contrasts with the definition of a guideline, which is generated through a systematic evaluation of the available evidence and usually assists with clinical decision making in a specific scenario [2]. The Arthritis and Musculoskeletal Alliance (ARMA) have defined standards of care for patients with connective tissue diseases, but nothing similar exists to address the specific needs of adults with myositis [3].
Polymyositis (PM), and other myositis subtypes, are classified as orphan diseases (ORPHA:98,482). The rarity and heterogeneity of myositis means that delayed diagnosis and misdiagnosis occur commonly [4]. Most clinicians are unfamiliar with the management of these chronic conditions and patients can feel isolated and unsupported [5]. To overcome some of these problems we surveyed the experiences of adults in the UK living with myositis and using a structured process have created patient-centred standards of care.
Methods
Steps taken to produce the patient-centred standards of care for adults with myositis
Step 1 - Initial information gathering from patients, relatives and caregivers |
• Focus group at Myositis UK AGM, July 2014 (30 participants) • Patient completed service evaluation questionnaire, March 2015 ○ 151 responses obtained |
Step 2 - Statement drafting |
• 15 draft statements reflecting optimum standards of care created by steering team. • Each statement addressed perceived deficits in current care arrangements as identified by patients |
Step 3 - Initial feedback |
• Feedback on draft statements sought from: ○ Myositis UK AGM, July 2015 (75 participants) ○ Members of the UK Myositis Network (UKMYONET) (responses from 12 individuals received) • Statements updated. One statement removed from process |
Step 4 - Modified Delphi exercise - Round one |
• 14 updated draft statements presented electronically to the Delphi panel (December 2015). Responses from 25 individuals received. • Level of agreement and suggestions for improvement analysed: ○ Eight statements met predetermined consensus level (mean level of agreement ≥8.5) ○ Six statements failed to meet predetermined consensus level. These were updated based on 40 individual items of feedback |
Step 5 - Modified Delphi exercise - Round two |
• Updated statements (n = 6) re-presented to panel (April 2016) • Three statements reached predetermined consensus level. • Remaining three statements were removed from the process |
Step 6 - Final production of the patient-centred Standard of Care |
• Approved updated statements arranged into three themes (December 2016) • Minor changes to grammar and readability of three statements • Creation of suggested audit standards to accompany each statement • Creation of plain language versions of each statement (January 2017) |
Initial information gathering from patients, relatives and caregivers
An initial focus-group of 30 participants (approximately 50% patients, 50% relatives/caregivers) was held at the Myositis UK (www.myositis.org.uk) Annual General Meeting (AGM) in July 2014. Information regarding the physical implications of disease and the social and emotional difficulties faced was gathered. These findings contributed to the development of a service evaluation questionnaire which was distributed by email and posted to all adult patient members of Myositis UK (n = 485) (Additional file 1 – Section One).
Statement drafting and initial feedback
Responses to the service evaluation questionnaire were analysed and 15 draft statements produced by agreement of the steering team (JBL, HC, JAL). Each reflected an optimum expected standard of care to address a matter highlighted by patients in the service evaluation questionnaire. These draft statements were then presented to attendees at the Myositis UK AGM in July 2015 and to members of the UK Myositis Network (UKMYONET) by email. Updating the statements in response to oral and written feedback received was overseen and agreed amongst the steering team.
Modified Delphi exercise
A modified, two-round Delphi consensus building exercise using a website-based survey system was then performed according to a pre-specified protocol. Briefly, the statements were sent to a multidisciplinary Delphi panel who were asked to indicate their level of agreement with each one using a ten point Likert scale, and to provide suggestions for improvement. A predetermined consensus level was agreed by the steering team (a mean agreement score ≥ 8.5 out of 10, unknown to the Delphi panel). Statements reaching this consensus level passed through to the final stage of the process. Where this level was not reached, suggestions for improvement were examined and incorporated into an updated version of the statements, which were then sent back to the panel. Those not reaching consensus at this point were removed from the list of standards. Twenty-eight patient representatives and healthcare professionals (including Allied Health Professionals, Rheumatologists and Neurologists) were invited to take part on the panel.
Final production
The final standards of care were grouped into domains. Suggested audit standards were produced, and plain language versions of the standards in a checklist format were agreed after a teleconference focus-group with patients, caregivers and Myositis UK charity representatives.
Statistics
A descriptive statistical analysis of the service evaluation questionnaire was performed (JBL). The mean and standard deviation (SD) were calculated where data were normally distributed, whereas medians and interquartile ranges (IQR) were calculated for non-normally distributed data. For hypothesis testing Fisher’s exact test or Mann Whitney rank-sum test were used where applicable. A p-value of <0.05 was considered as significant.
Results
Initial information gathering from patients, relatives and caregivers
In total, 151 responses (31% [151/485] return rate, 145 online and 6 by post) to the service evaluation questionnaire were obtained. Patients with dermatomyositis (DM) (37%), PM (27%) and inclusion body myositis (36%) participated. The mean age of respondents was 59 years (SD 14) and 33% were male. Diagnostic delays were common, particularly between presentation to the general practitioner and onwards referral to secondary care (median interval 2 months [IQR 0–4]). The majority of patients (58%) had been given at least one incorrect diagnosis prior to their final accurate diagnosis.
Satisfaction levels regarding access to Allied Healthcare Professionals were low to moderate (19% satisfied with access to rehabilitation services, 51% to physiotherapy and 55% to occupational therapy). Most respondents (83%) were unaware of any local support groups for patients with myositis. In addition, low levels of satisfaction were reported regarding the management of extra-muscular and non-medical aspects of the disease. For example, only 23% of patients were satisfied that they had received sufficient support relating to employment issues, and only 24% stated that psychological aspects had being adequately addressed.
Overall, 54% of patients reported that they had received satisfactory counselling about potential adverse effects of treatments and 64% were confident that they could obtain urgent medical advice regarding their myositis, e.g. in the event of a disease flare. Furthermore, 69% of those with IBM were reviewed by a specialist less than once annually. Only 33% of patients indicated that they had been invited to participate in myositis research studies.
Statement drafting, feedback and updating
Fifteen draft statements were created, of which 13 were changed after feedback from attendees at the Myositis UK AGM 2015 (n = 75) and UKMYONET (12 responses, 57 individual items of feedback). One statement was removed from the process at this stage due to overwhelmingly negative feedback from both sources (Additional file 1 – Section Two).
Full results of the modified Delphi exercise are detailed in the Additional file 1 (Section Three). In the first round, responses were received from 24 of the 28 (86%) invited panel members. Eight of the 14 statements met the pre-determined consensus agreement level (a mean agreement score ≥ 8.5 out of 10). Forty items of feedback were received regarding the statements not reaching this consensus level. Analysis of this feedback informed statement updates, agreed amongst the steering team. During this process, one deviation from the protocol occurred where a statement was slightly refocussed by the steering team, to ensure that a key area of concern from the service evaluation questionnaire (the low levels of satisfaction regarding management of psychological aspects) was addressed.
In the second round of the Delphi exercise, 21 responses from 28 invitations (75%) were obtained. Despite the modifications, three statements failed to reach the pre-determined consensus level (mean agreement levels: 6.9, 8.1, 8.2) and were therefore removed from the process. The three remaining ones (mean agreement levels: 8.7, 9.1, 9.3) passed to the final stage.
Final production
Final patient-centred standards of care for adults with myositis and accompanying plain language versions of the standards
Patient-centred standards of care | Plain language version of standards | ||
|---|---|---|---|
Domain 1: Presentation, referral and diagnosis | |||
Myositis should be considered in patients with unexplained weakness, fatigue, rash, myalgia or arthralgia • Testing of serum CK is a useful screening tool, but can be normal in some scenarios | 9.1 | When I first developed symptoms of myositis, was the correct diagnosis considered early? | |
GPs should identify patients presenting with features of myositis (e.g. muscle weakness, raised CK +/− rash) and refer to a specialist as soon as this diagnosis is considered | 8.8 | Was I referred to an appropriate specialist quickly? | |
Domain 2: Care arrangements and the interaction between myositis specialists and other healthcare professionals | |||
Patients with myositis should be under the care of a specialist with specific expertise and experience in managing myositis • This could be either directly or as part of a formal shared-care agreement with a local physician | 9.5 | Am I under the care of a specialist (either directly or under shared-care) who is experienced and competent in the management of patients with myositis? | |
Patients with myositis should continue to be periodically reviewed by a myositis specialist for as long their disease is active or muscle strength continues to deteriorate • This could be either directly or as part of a formal shared-care agreement with a local physician | 9.1 | Do I see my specialist with sufficient frequency to meet my needs? | |
The services for patients with myositis should include access to ongoing specialist physiotherapy, occupational therapy and speech and language therapy • This could be integrated in to the specialist clinic or via a formal shared-care agreement between specialist and non-specialist (local) therapists | 9.2 | Do I have adequate support from other health professionals (including physiotherapists, occupational therapists and speech and language therapists) that have experience in managing patients with myositis? | |
There should be clear protocols defining how patients with myositis should seek urgent advice. • For example, the specialist centre might provide a dedicated telephone advice line for patients and other healthcare professionals | 8.9 | Should the need arise, am I able to obtain appropriate urgent medical advice regarding my myositis or its treatment? | |
Domain 3: Disease management and holistic care | |||
When considering starting patients with myositis on immunosuppression, detailed discussion regarding the potential benefits and possible side effects must take place. • This could be reinforced by other members of the multidisciplinary team (e.g. pharmacist) • Formal shared-care agreements with GPs should also be in place | 8.8 | Before I am offered treatments for my myositis, do I understand the relevant benefits and potential risks? | |
Healthcare professionals should specifically address extra-muscular symptoms such as pain, fatigue and depression at each consultation | 8.7 | Are issues such as pain, fatigue or low mood addressed in addition to my muscle weakness during consultations with my specialist? | |
Services for patients with myositis should provide holistic care that addresses physical and psychological aspects of disease and its social implications • For example, this may include difficulties with employment | 8.7 | If required, do I have access to support with how myositis affects my day-to-day life (for example, the effect on my job)? | |
Patients with myositis should be signposted to appropriate information resources and patient groups | 9.3 | Have I been made aware of relevant myositis information resources and patient groups? | |
Patients with myositis should be offered participation in clinical trials as part of routine practice | 8.8 | Have I been offered participation in clinical trials for myositis? | |
Discussion
Our patient-centred approach has helped to create a set of unique standards of care for adults with myositis. By specifically addressing deficiencies in care highlighted by patients and then using an iterative process that considered feedback from patients, relatives, caregivers and healthcare professionals, we have produced standards of care tailored to the individual healthcare needs of patients with myositis.
The service evaluation questionnaire involved a wide variety of patients with myositis living in England, Scotland and Wales, thus capturing a variety of experiences and views. In addition to patient representatives, the Delphi panel also represented a range of healthcare professionals from diverse geographic locations, minimising bias from one professional group or location. However, there is the possibility that not all relevant stakeholders have been included and we have not included feedback or approval from those with juvenile-onset myositis (i.e. Juvenile-onset DM). It is acknowledged that some aspects of the produced standards may apply more to certain subgroups of myositis patient than others. Similarly, our work is derived from views regarding the UK healthcare system, and may therefore not be applicable or relevant in other locales.
Implementation of the standards would require additional resources, e.g. to improve access to Allied Healthcare Professionals, such as physiotherapists who have experience in caring for and managing patients with myositis. However, other standards could be quickly implemented, e.g. an up-to-date list of ongoing myositis clinical trials and the production of patient information resources that can be kept in clinics for access during consultations.
Despite the potential to improve the quality of healthcare, there is often inconsistent implementation of new research findings or practice recommendations [6]. Several barriers to implementation have been identified and various solutions offered [7, 8]. The process undertaken to create these standards of care is consistent with several of these recommendations. Importantly, there has been prominent patient and caregiver involvement throughout to ensure acceptability and appropriateness of the standards. We have also created plain language statements in collaboration with patient charity representatives. These will be disseminated by Myositis UK and via the active myositis social media community. From the perspective of the clinician we have facilitated dissemination and implementation of the standards of care by publishing this manuscript Open Access and have minimised the volume of information by presenting the standards as a single accessible table. Implementation measures, including an assessment of adoption and coverage of the standards of care, will be assessed after 12 months and reported through UKMYONET and Myositis UK.
We anticipate that these standards of care for adults with myositis will support clinicians, benefit patients and reduce variation by providing a benchmark of good practice that local services can be assessed against. As a consequence, we seek to mirror the improvements in practice seen in the management of stroke and epilepsy observed since the commencement of national audit programmes for these conditions [9, 10].
Conclusion
Healthcare provision for patients with myositis is inconsistent. Consequently, many patients feel isolated and unsupported. Our service evaluation questionnaire identified common issues relating to diagnostic delays, poor access to specialists and allied healthcare professionals with experience in the care of patients with myositis, difficulties obtaining urgent medical advice, inadequate counselling regarding the risks of medications and poor management of extramuscular symptoms.
To address these issues, we have created patient-centred standards of care for adults with myositis. To facilitate implementation, plain language versions of the standards and an audit tool have been created. Implementation of these standards of care in the UK will promote consistent good practice and improve healthcare quality for patients with myositis.
Abbreviations
- AGM:
-
Annual General Meeting
- ARMA:
-
Arthritis and Musculoskeletal Alliance
- DM:
-
Dermatomyositis
- GP:
-
General practitioner
- IIM:
-
Idiopathic inflammatory myopathies
- IQR:
-
Interquartile range
- PM:
-
Polymyositis
- SD:
-
Standard deviation
- UKMYONET:
-
UK Myositis Network
Declarations
Acknowledgements
The authors thank all patients, families and healthcare professionals contributing to this study. The authors also thank the Myositis UK Executive Committee and all members of Myositis UK for allowing presentation at their annual general meeting and facilitating completion of the service evaluation questionnaire.
Myositis UK is a registered charity providing information and support to individuals and their families affected by Dermatomyositis, Polymyositis, Inclusion Body Myositis and Juvenile Dermatomyositis.
UK Myositis Network (UKMYONET) members providing feedback:
Robert G Cooper, Professor of Rheumatology, MRC-ARUK Institute for Ageing and Chronic Disease, University of Liverpool.
Christopher Edwards, Professor of Rheumatology, University Hospital Southampton NHS Foundation Trust.
David Hilton-Jones, Consultant Neurologist, Oxford University Hospitals NHS Foundation Trust.
David Isenberg, Professor of Rheumatology, University College London Hospitals NHS Foundation Trust.
Patrick Kiely, Consultant Rheumatologist, St George’s University Hospitals NHS Foundation Trust.
Heidi Lempp, Senior Lecturer in Medical Sociology, Kings College London.
Neil McHugh, Professor of Pharmacoepidemiology, University of Bath.
Pedro Machado, NIHR RD TRC Postdoctoral Fellow & Honorary Consultant in Rheumatology and Muscle Diseases, MRC Centre for Neuromuscular Diseases & Centre for Rheumatology, University College London.
John Pauling, Senior Lecturer and Consultant Rheumatologist, Royal National Hospital for Rheumatic Diseases.
Sarah Tansley, Clinical Research Fellow, Royal National Hospital for Rheumatic Diseases.
John Winer, Consultant Neurologist, University Hospitals Birmingham NHS Foundation Trust.
Delphi panel participants:
Shirley Caldwell, Senior Rheumatology Research Coordinator, Salford Royal NHS Foundation Trust.
Robert G Cooper, Professor of Rheumatology, MRC-ARUK Institute for Ageing and Chronic Disease, University of Liverpool.
Shouma Dutta, Consultant Rheumatologist, Staffordshire and Stoke-on-Trent Partnership NHS Trust.
Christopher Edwards, Professor of Rheumatology, University Hospital Southampton NHS Foundation Trust.
Nagui Gendi, Consultant Rheumatologist, Basildon and Thurrock University Hospitals NHS Foundation Trust.
Joanne Goode, Patient representative and Myositis UK Treasurer.
Patrick Gordon, Consultant Rheumatologist, King’s College Hospital NHS Foundation Trust.
Will Gregory, Specialist Rheumatology Physiotherapist and Advanced MSK Practitioner, Salford Royal NHS Foundation Trust.
David Hilton-Jones, Consultant Neurologist, Oxford University Hospitals NHS Foundation Trust.
Patrick Kiely, Consultant Rheumatologist, St George’s University Hospitals NHS Foundation Trust.
Heidi Lempp, Senior Lecturer in Medical Sociology, Kings College London.
Pedro Machado, NIHR RD TRC Postdoctoral Fellow & Honorary Consultant in Rheumatology and Muscle Diseases, MRC Centre for Neuromuscular Diseases & Centre for Rheumatology, University College London.
Neil McHugh, Professor of Rheumatology, Royal National Hospital for Rheumatic Diseases.
James Miller, Consultant Neurologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust.
Paula Jordan, Patient representative and Myositis UK General Secretary.
John Pauling, Senior Lecturer and Consultant Rheumatologist, Royal National Hospital for Rheumatic Diseases.
Fiona Pearce, Clinical Lecturer in Rheumatology, University of Nottingham.
Michael Rose, Consultant Neurologist King’s College Hospital NHS Foundation Trust.
Jade Skeates, Specialist Rheumatology Physiotherapist, Royal National Hospital for Rheumatic Diseases.
Sarah Tansley, Clinical Research Fellow, Royal National Hospital for Rheumatic Diseases.
Paul Truepenny, Patient representative.
Yvonne Truepenny, Relative/caregiver.
David Tucker, Patient representative.
John Winer, Consultant Neurologist, University Hospitals Birmingham NHS Foundation Trust.
Participants in focus group to create plain language versions of statements:
Paul Truepenny, Patient representative.
Yvonne Truepenny, Relative/caregiver.
David Tucker, Patient representative.
Irene Oakley, Patient representative (relative/caregiver) and Myositis UK Group Coordinator.
Joanne Goode, Patient representative and Myositis UK Treasurer.
Steering team.
James B Lilleker, Clinical Research Fellow, The University of Manchester.
Hector Chinoy, Senior Lecturer and Consultant Rheumatologist, The University of Manchester.
Janine Lamb, Reader, The University of Manchester.
We wish to thank those who reviewed the manuscript for their constructive comments (Additional file 2).
Funding
This study was supported in part by Arthritis Research UK (18474), the Medical Research Council (MR/N003322/1) and the UK Myositis Network (UKMYONET). UKMYONET is supported by the Manchester Academic Health Science Centre (MAHSC).
This report includes independent research supported by the NIHR Biomedical Research Unit Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Availability of data and materials
Summary data is contained in this manuscript and in the supplementary materials. The full dataset used and/or analysed during the current study are available from the corresponding author on reasonable request.
Authors’ contributions
HC, PG and PJ had the original idea for this project. JBL, JAL and HC formed the steering committee and agreed on the draft statements and any changes made in response to feedback. JBL organised and analysed the service evaluation questionnaire and modified Delphi process and facilitated the final focus group to create plain language versions of the statements and the audit tool. JBL drafted the manuscript. HL, MER and RGC critically reviewed the intellectual content of the draft manuscript. All authors critically reviewed the draft manuscript, approved the final version and agree to be accountable for all aspects of the work.
Ethics approval and consent to participate
We invited members of the charity group Myositis UK to complete a service evaluation questionnaire and in some cases also participate in the Delphi panel and focus group to produce plain-language versions of the standards of care. We used the Health Research Authority (HRA) decision tools (http://www.hra-decisiontools.org.uk/) to determine that our project was not research and that research ethics approval was not required. Participants were not randomised to different groups, no changes to treatment or any other standard clinical care procedures were made or recommended, and the findings were not generalisable (i.e. outcomes are only of interest to the specific clinical area considered). Specific consent for participation was therefore not obtained.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
References
- Furst DE, Amato AA, Iorga ŞR, Gajria K, Fernandes AW. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012;45:676–83.View ArticlePubMedGoogle Scholar
- Stoffer MA, Smolen JS, Woolf A, et al. Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. Ann Rheum Dis. 2015;74:1145–9.View ArticlePubMedGoogle Scholar
- Arthritis and Musculoskeletal Alliance. Standards of Care for people with Connective Tissue. Diseases. 2007;Google Scholar
- Meyer A, Meyer N, Schaeffer M, Gottenberg J-EJ-E, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology. 2015;54:50–63.View ArticlePubMedGoogle Scholar
- Truepenny P, Kaushik V, Lempp H. Polymyositis. BMJ. 2012;344:e1181.View ArticlePubMedGoogle Scholar
- Flodgren G, Hall AM, Goulding L, et al. Tools developed and disseminated by guideline producers to promote the uptake of their guidelines. Cochrane database Syst Rev. 2016:CD010669.Google Scholar
- Schipper K, Bakker M, De Wit M, Ket JCF, Abma TA. Strategies for disseminating recommendations or guidelines to patients: a systematic review. Implement Sci. 2015;11:82.View ArticleGoogle Scholar
- Cabana MD, Rand CS, Powe NR, et al. Why Don’t Physicians Follow Clinical Practice Guidelines? JAMA. 1999;282:1458.View ArticlePubMedGoogle Scholar
- Dixon PA, Kirkham JJ, Marson AG, Pearson MG. National Audit of Seizure management in Hospitals (NASH): results of the national audit of adult epilepsy in the UK. BMJ Open. 2015;5:e007325.View ArticlePubMedPubMed CentralGoogle Scholar
- Rudd AG, Irwin P, Rutledge Z, et al. The national sentinel audit for stroke: a tool for raising standards of care. J R Coll Physicians Lond. 1999;33:460–4.PubMedGoogle Scholar
